UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

The New England journal of medicine, 2019-10, Vol.381 (16), p.1535-1546

2019

Volltextzugriff (PDF)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (11), p.1961-1973

2021

Volltextzugriff (PDF)

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma

Cancer immunology research, 2021-10, Vol.9 (10), p.1202-1213

2021

Volltextzugriff (PDF)

A Machine‐Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma

Clinical pharmacology and therapeutics, 2020-04, Vol.107 (4), p.978-987

2020

Volltextzugriff (PDF)

Association of early tumor growth rate and survival outcomes in first-line metastatic non–small cell lung cancer (mNSCLC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9063-9063

2022

Volltextzugriff (PDF)

Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10043-10043

2020

Volltextzugriff (PDF)

Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT037-CT037

2019

Volltextzugriff (PDF)

Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9568-9568

2019

Volltextzugriff (PDF)

Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI: CheckMate 067 4-year data

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9551-9551

2019

Volltextzugriff (PDF)

CheckMate 067: Long-term outcomes in patients with mucosal melanoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10019-10019

2020

Volltextzugriff (PDF)

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9501-9501

2019

Volltextzugriff (PDF)

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

The lancet oncology, 2018-11, Vol.19 (11), p.1480-1492

2018

Volltextzugriff (PDF)

CovCopCan: An efficient tool to detect Copy Number Variation from amplicon sequencing data in inherited diseases and cancer

PLoS computational biology, 2020-02, Vol.16 (2), p.e1007503-e1007503

2020

Volltextzugriff (PDF)

Abstract PO-045: Observational study assessing survival outcomes in advanced melanoma patients with brain metastases treated with immunotherapy with or without radiotherapy: Effect of radiotherapy sequence and modality

Clinical cancer research, 2021-04, Vol.27 (8_Supplement), p.PO-045-PO-045

2021

Volltextzugriff (PDF)

A rare presentation of sexsomnia in a military service member

Journal of clinical sleep medicine, 2021-01, Vol.17 (1), p.107-109

2021

Volltextzugriff (PDF)

Hereditary predisposition to malignant myeloid hemopathies: Caution in use of saliva and guideline based on our experience

Frontiers in oncology, 2023-02, Vol.13, p.1120829

2023

Volltextzugriff (PDF)

Comparison with Private and Public Clonotypes Reveals That, While CLL Type Stereotyped BCR Are Produced in 90% of Healthy Subjects from 18 to 78 Years, They Are Not Accumulated and Are Mostly Found in Immature and Naïve B-Cells

Blood, 2021-11, Vol.138 (Supplement 1), p.2621-2621

2021

Volltextzugriff (PDF)

A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia

International Journal of Laboratory Hematology, 2021-08, Vol.43 (4), p.683-692

2021

Volltextzugriff (PDF)

Exposure to Major Vector-Borne Diseases in Dogs Subjected to Different Preventative Regimens in Endemic Areas of Italy

Pathogens (Basel), 2021-04, Vol.10 (5), p.507

2021

Volltextzugriff (PDF)

PB1819: KMT2A::ARHGEF12 RARE FUSION ASSOCIATED WITH A NOVEL GERMLINE DDX41 VARIANT IN ACUTE MYELOID LEUKEMIA

HemaSphere, 2023-08, Vol.7 (S3), p.e173837c-n/a

2023

Volltextzugriff (PDF)

Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer

Journal of clinical oncology, 2023-05, Vol.41 (15), p.2800-2814

2023

Volltextzugriff (PDF)

Abstract 2273: A machine learning approach to identify a peripheral prognostic cytokine signature via nivolumab clearance in patients with advanced melanoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2273-2273

2019

Volltextzugriff (PDF)

Unpublished Mediterranean records of marine alien and cryptogenic species

Bioinvasions records, 2020, Vol.9 (2), p.165-182

Katsanevakis, Stelios

2020

Volltextzugriff (PDF)

Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease

Alzheimer's & dementia, 2024-08, Vol.20 (8), p.5236-5246

2024

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(31)
Berichte
(1)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(27)
Publisher or Other Site
(17)
LWW Total
(16)
MEDLINE
(10)
Ingenta
(9)
IngentaConnect Journals
(6)
Wiley-Blackwell Journals
(5)
Wiley Online Library
(2)
Elsevier ScienceDirect Journals Complete
(2)
Oxford Journals
(1)
Oxford Journals 2020 Medicine
(1)

6 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma

A Machine‐Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma

Association of early tumor growth rate and survival outcomes in first-line metastatic non–small cell lung cancer (mNSCLC)

Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067

Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma

Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI)

Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI: CheckMate 067 4-year data

CheckMate 067: Long-term outcomes in patients with mucosal melanoma

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204)

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

CovCopCan: An efficient tool to detect Copy Number Variation from amplicon sequencing data in inherited diseases and cancer

Abstract PO-045: Observational study assessing survival outcomes in advanced melanoma patients with brain metastases treated with immunotherapy with or without radiotherapy: Effect of radiotherapy sequence and modality

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

A rare presentation of sexsomnia in a military service member

Hereditary predisposition to malignant myeloid hemopathies: Caution in use of saliva and guideline based on our experience

Comparison with Private and Public Clonotypes Reveals That, While CLL Type Stereotyped BCR Are Produced in 90% of Healthy Subjects from 18 to 78 Years, They Are Not Accumulated and Are Mostly Found in Immature and Naïve B-Cells

A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia

Exposure to Major Vector-Borne Diseases in Dogs Subjected to Different Preventative Regimens in Endemic Areas of Italy

PB1819: KMT2A::ARHGEF12 RARE FUSION ASSOCIATED WITH A NOVEL GERMLINE DDX41 VARIANT IN ACUTE MYELOID LEUKEMIA

Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer

Abstract 2273: A machine learning approach to identify a peripheral prognostic cytokine signature via nivolumab clearance in patients with advanced melanoma

Unpublished Mediterranean records of marine alien and cryptogenic species

Pharmacoepidemiology evaluation of bumetanide as a potential candidate for drug repurposing for Alzheimer's disease

Suchergebnisse filtern